News Summary
PositiveRepligen delivered solid Q2 2026 results with 13% organic revenue growth and raised full-year guidance to 10.5-13.5%, while announcing a strategically significant $31.00/share acquisition of BioLife Solutions to accelerate cell therapy capabilities. The BioLife deal is expected to be accretive by 5+ cents in year 1 and 25+ cents in year 2 with $20M+ synergies, though execution risk remains as closing is contingent on Q4 2026 regulatory and shareholder approvals.
Red flags
- •BioLife acquisition closing contingent on Q4 2026 regulatory approvals and shareholder votes—execution risk present
- •Guidance excludes BioLife contribution, making comparability difficult for FY2026 and forward projections
- •Modest 12% reported revenue growth in Q2 reflects some deceleration from prior trends, though organic growth of 13% offsets this concern
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 2.0M | +466K | $271M | 2.4% | +31% | Existing |
| Point72 | Steve Cohen | 166K | +166K | $23M | <0.1% | — | NEW |
| Duquesne Family Office | Stanley Druckenmiller | 77K | +77K | $11M | 0.2% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where RGEN ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #16 of this fund's book
- 13MICROSOFT CORP$310M
- 14RTX CORPORATION$294M
- 15CAPITAL ONE FINL CORP$278M
- 16REPLIGEN CORP$271M
- 17PHILIP MORRIS INTL INC$264M
- 18VISA INC$258M
- 19BOSTON SCIENTIFIC CORP$253M
Values are quarter-end position sizes. Shown only for funds where RGEN ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Garland Jason K | CFO | SELL | 530 | $150.00 | $0.08M | 2026-07-16 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | SC 13G/A | 1.8M | 3.1% | 2026-08-14 | ↗ |
| Vanguard Capital Management | SC 13G | 2.8M | 5.0% | 2026-07-31 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.